Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood

被引:0
作者
Radek Frič
Bernt Johan Due-Tønnessen
Tryggve Lundar
Arild Egge
Bård Kronen Krossnes
Paulina Due-Tønnessen
Einar Stensvold
Petter Brandal
机构
[1] Oslo University Hospital,Department of Neurosurgery
[2] Oslo University Hospital,Department of Pathology
[3] Oslo University Hospital,Department of Radiology and Nuclear Medicine
[4] Oslo University Hospital,Department of Pediatrics
[5] Oslo University Hospital,Department of Oncology
[6] University of Oslo,Faculty of Medicine
来源
Scientific Reports | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the study was to analyze the long-term outcome (>20 years) after treatment of posterior fossa medulloblastoma (MB) in childhood. We analyzed data from patients treated for posterior fossa MB between 1974 (introduction of the first international treatment protocol in Norway) and 1987 (when use of radiotherapy was abandoned in children under 4 years of age). Out of 47 children, 24 survived >20 years. At the time of analysis, 16 patients (median age 41 years, range 32–52) were alive (median follow-up 34 years, range 30–42), while 8 patients died 22–41 years (median 31 years) after primary treatment: one late death (after 22 years) was due to tumor recurrence whilst other 7 deaths (after 23 to 41 years) were related to the detrimental effects of the treatment (secondary tumors, stroke, severe epilepsy and depression). Observed 20- and 30-year survival rates were 51% and 44%, respectively. Despite successful treatment of MB in childhood and satisfactory tumor control during the first 20 years following primary treatment, our data indicates that even long-term survivors may die from tumor recurrence. However, the main factors causing late mortality and morbidity in long-term survivors seem to be the complications related to radiotherapy given in childhood.
引用
收藏
相关论文
共 72 条
[1]  
Desandes E(2014)Incidence and survival of children with central nervous system primitive tumors in the French National Registry of Childhood Solid Tumors Neuro Oncol 16 975-983
[2]  
Guissou S(2009)Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91 Eur J Cancer 45 1209-1217
[3]  
Chastagner P(2014)Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review Childs Nerv Syst 30 979-990
[4]  
Lacour B(2011)Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes Neuro Oncol 13 536-545
[5]  
von Hoff K(2005)Outcome of medulloblastoma in children: long-term complications and quality of life Neuropediatrics 36 357-365
[6]  
Gudrunardottir T(2014)Physical functioning in pediatric survivors of childhood posterior fossa brain tumors Neuro Oncol 16 147-155
[7]  
Edelstein K(1969)The treatment and prognosis of medulloblastoma in children. A study of 82 verified cases Am J Roentgenol Radium Ther Nucl Med 105 43-62
[8]  
Ribi K(1990)Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I) Eur J Cancer 26 464-469
[9]  
Piscione PJ(2019)Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study J Clin Oncol 37 731-740
[10]  
Bouffet E(2016)Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study Lancet Oncol 17 287-298